Lipid pattern in middle-aged inhabitants of the Lower Silesian region of Poland. The PURE Poland sub-study
More details
Hide details
Department of Internal and Occupational Medicine and Hypertension, Wroclaw Medical University, Poland
Department of Social Medicine, Wroclaw Medical University, Wroclaw, Poland
Department of Dietetics, Wroclaw Medical University, Wroclaw, Poland
Department of Food Science and Dietetics, Wroclaw Medical University, Wroclaw, Poland
Cancer Epidemiology and Prevention Division; The Maria Sklodowska-Curie Memorial, Cancer Center and Institute of Oncology, Warsaw, Poland
Ann Agric Environ Med. 2013;20(2):317–324
A decreased serum high density lipoprotein-cholesterol (HDL-C) is a strong predictor of cardiovascular risk. However, total HDL is a very dynamic, changeable fraction, and does not perform the function of atherosclerosis markers. In the presented study, the pattern of serum lipids, including HDL-C subclasses (HDL2- and HDL3-cholesterol), in a middle- aged Polish Lower Silesia population was defined.

Material and Methods:
A group of 746 males and 1,298 females, aged 35–70, were investigated. All subjects were participants in the PURE study. Mean serum lipid levels were determined for groups selected on the basis of gender, age, cigarette smoking, drinking alcohol and place of residence (urban/rural area). The data were analyzed using STATISTICA 6.0 PL.

In multiple linear regression models, age was the most important independent and consistent predictor of total cholesterol (TC) and LDL cholesterol (LDL-C). The prevalence of low HDL-C (threshold 40 mg/dL in males, 50 mg/dL in females) was 16.5% for males and 22.6% for females. This gender-conditioned difference in the prevalence of low HDL-C was greater in rural (20.0% vs. 30.9%, respectively, in males and females) in comparison to urban (14.4% vs. 17.1%) areas. The lipid pattern was significantly worse in rural than in urban females. Female rural inhabitants showed higher triglycerides (TG) and lower HDL cholesterol (total and contained in subclasses HDL2 and HDL3). Simultaneously, a higher BMI, higher percent of smokers and drinkers and lower age of smoking female rural inhabitants in comparison to urban females were estimated. In the total population, cigarette smoking or drinking alcohol were associated with significant increases in TC, LDL-C and TG, also with decreased HDL-C (smoking) or HDL2-C (drinking). Two-way analysis of variance showed the existence of interaction between these risk factors in their influence on HDL-C and HDL3-C.

In the middle-aged population of the Lower Silesian region in Poland the place of residence (urban/rural area) had a significant impact on the lipid pattern. This pattern is more atherogenic in rural women than in urban women.

European Heart Network. Cardiovascular disease statistics. http:// 2008 edition.
Panico S, Mattiello A. Epidemiology of cardiovascular diseases in women in Europe. Nutrition, Metabolism Cardiovascular Dis. 2010; 20: 379–85.
Fogarty P, O’Beirne B, Casey C. Epidemiology of the most frequent diseases in the European a-symptomatic post-menopausal women. Is there any difference between Ireland and the rest of Europe? Maturitas 2005; 52S: S3-S6.
Despres JP, Lemieux I, Dagienais GR, et al. HDL-cholesterol as a marker of coronary heart disease risk: the Quebec cardiovascular study. Atherosclerosis 2000; 153: 263–72.
Tanne D, Yari S, Goldbourt U. High- density lipoprotein cholesterol and risk of ischemic stroke mortality. A 21- year follow-up of 8586 men from the Israeli Ischemic. Heart Disease Study. Stroke 1997; 281: 83–87.
Veverling-Rijnsburger AW, Jonkers IJ, van Exel E, Gussekloo J, Westerdrop RG. High density vs low density lipoprotein cholesterol as the risk factor of coronary artery disease ad stroke in old age. Arch Intern Med. 2003; 163(13): 1549–54.
Pedersen TR, Olsson AG, Faergman O, et al. for The Scandinavian Simvastatin Survival Study Group. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S) Circulation. 1998; 97: 1453–60.
Rubins HB, Robins SJ, Collins D, et al. for the Veterans Affairs HighDensity Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999; 341: 410–8.
Oram JF. HDL apolipoproteins and ABCA1: partners in the removal of excess cellular cholesterol. Arterioscler Thromb Vasc Biol. 2003; 23: 720–7.
Barter P. HDL: a recipe for longevity. Atherosclerosis 2004; 5: 25–31.
Murphy AJ, Chin-DustingJP, Sviridov D, Woolard KJ. The antiinflammatory effects of high density lipoproteins. Curr Med Chem. 2010; 16: 667–75.
Kontush A, Therond P, Zerrad A, Couturier M, Negre-Salvayre A, de Souza JA, Chantepie S, Chapman MJ. Preferiential sphingosine1-phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities. Ath Thromb Vasc. 2007; 27(8): 1843–9.
Nofer JR, Levkau B, Wolinska I et al. Supression of endothelial cell apoptosis by high density lipoprotein (HDL) and HDL asssociated lysosphingolipids. J Biol Chem. 2001; 276: 43480–5.
Li D, Weng S, Yang B, Zander DS, Saldsen T, Nichols WW, Khan S, Metha JL. Inhibition of arterial thrombus formation by apo AI Milano. Arteriosc Thromb Vasc Biol. 1999; 19: 378–83.
Nofer JR, Giet M, Tolle M, Wolinska I, Wnuck Lipinski K, et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest. 2004; 113: 560–81.
Nofer JR, Kehre B, Fobker M, Levkau B, Assman G, von Eckardstein A. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis. 2002; 161: 1–16.
Van Lenten BJ, Wagner AC, Nayak DP, Hama S, Navab M, Fogelman AM. High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection. Circulatory 2001; 103: 2283–8.
Gomaraschi M, Conca P, Favari E, Sinagra G, Bernini F, Franceschini G, Calabresi L. Relationship between inflammation-induced structural changes of HDL and atheroprotective functions. 6th IAS-Sponsored Workshop on High Density Lipoproteins, Westin, Whisler, Canada May 17–20, 2010, Abstract Book, P-063.
Smith JD. Myeloperoxidase, Inflammation, and Dysfunctional HDL. J Clin Lipidol. 2010; 4(5): 382–8.
Le N, Epperson M, Gosmanova E, Gletsu N, Lin E, Wilson P. Acute changes in antioxidant properties of plasma high-density lipoproteins. 6th IAS-Sponsored Workshop on High Density Lipoproteins, Westin, Whisler, Canada, May 17–20, 2010, Abstract Book, P-070.
Berg CM, Lissner L, Aires N, Lappas G, Tore´n K, Wilhelmsen L, et al. Trends in blood lipid levels, blood pressure, alcohol and smoking habits from 1985 to 2002: results from INTERGENE and GOT-MONICA. Eur J Cardiovasc Prev Rehabil. 2005; 12: 115–125.
Berns MAM, de Vries JHM, Katan MB. Determinants of the increase of serum cholesterol with age: a longitudinal study. Int J Epidemiol. 1988; 17(4): 789–796.
Ferrara A, Barrett-Connor E, Shan J. Total, LDL, and HDL cholesterol decrease with age in older men and women. The Rancho Bernardo Study 1984–1994. Circulation. 1997; 96: 37–43.
Freedman DS, Otvos JD, Jeyarajah EJ, Shalaurova I, Cupples LA, Parise H, et al. Sex and age differences in lipoprotein subclasses measured by nuclear magnetic resonance spectroscopy: the Framingham Study. Clin Chem. 2004; 50: 1189–1200.
Ai M, Otokozawa S, Asztalos BF, Ito Y, Nakajima K, White CC, Cupples LA, Wilson PW, Schaefer EJ. Small dense LDL cholesterol and coronary heart disease: results from the Framingham Offspring Study. Clin Chem. 2010; 56(6): 967–76. Epub 2010 Apr.29.
Stone NJ, Bilek S, Rosenbaum S.Strona NCEPT ATP III. Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options. Am J Cardiol. 2005; 96(4A): 53E-59E.
Rouvre M, Vol S, Gusto G, Born C, Lantieri O, Tichet J, Lecomte P. Low high density lipoprotein cholesterol: prevalence and associated riskfactors in a large French population. Ann Epidemiol. 2011; 21(2): 118–27.
Pannier B, Thomas F, Eschwe`ge E, Bean K, Benetos A, Leocmach Y, et al. Cardiovascular risk markers associated with the metabolic syndrome in a large French population: the SYMFONIE study. Diabetes Metab. 2006; 32: 467–474.
Ostlund RE, Staten M, Kohrt WM, Schultz J, Malley M. The Ratio of Waist-to-Hip Circumference, Plasma Insulin Level, and Glucose Intolerance as Independent predictors of the HDL2 cholesterol level in older adults. N J Eng Med. 1990; 322(4): 229–34.
Kolovou GD, Anagnostopoulou K, Pilatis ND, et al. Fasting serum triglyceride and high-density lipoprotein cholesterol levels in patients intended to be treated for dyslipidemia. Vasc Health Risk Manag. 2005; 1: 155–61.
Kolovou GD, Anagnostopoulou KK, Salpea KD, et al. Influence of triglycerides on other plasma lipids in middle-aged men intended for hypolipidaemic treatment. Hellenic J Cardiol. 2006; 47: 78–83.
Pownall HJ, Brauchi D, Kilinç C, et al. Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis 1999; 143: 285–97.
Denke MA, Sempos CT, Grundy SM. Excess body weight. An underrecognized contributor to dyslipidemia in white American women. Arch Intern Med. 1994; 154(4): 401–410.
Jennings C, Kotseva K, De Backer G, Keil U, Wood D. Time trends in smoking in coronary patients the EUROASPIRE Surveys I, II and III in 8 countries. Eur J Cardiovasc Nurs. 2008; 7: S25–6.
Gupta R. Recent trends in coronary heart disease epidemiology in India. Indian Heart J. 2008; 60(2 Suppl B): B4–18.
Ruixing Y, Shangling P, Hong C, Hanjun Y, Hai W, Yuming C, Jinzhen W, Feng H, Meng L, Muyan L. Diet, alcohol consumption, and serum lipid levels of the middle-aged and elderly in the Guangxi Bai Ku Yao and Han populations. Alcohol. 2008; 42(3): 219–29.
Ruidavets JB, Ducimetière P, Evans A, Montaye M, Haas B, Bingham A, et al. Patterns of alcohol consumption and ischaemic heart disease in culturally divergent countries: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). BMJ 2010; 341: c6077. doi: 10.1136/bmj.c6077.
Dai WS, Horn DL, Kuller LH, D’Antonio JA, Gutai JP, Wozniczak M, Wohlfahrt B. Alcohol consumption and high density lipoprotein cholesterol concentration among alcoholics. Am J Epidemiol. 1985; 122: 620–7.
Mäkelä SM, Jauhiainen M, Ala-Korpela M, Metso J, Lehto TM, Savolainen MJ, Hannuksela ML. HDL2 of heavy alcohol drinkers enhances cholesterol efflux from raw macrophages via phospholipidrich HDL2b particles. Alkohol Clin Exp Res. 2008; 32(6): 991-1000.